Are metformin and Ozempic in the same drug class?

No. The metformin label describes it as a biguanide. The Ozempic label describes semaglutide as a GLP-1 receptor agonist. They are different classes with different mechanisms and different boxed warnings.

Is metformin approved for weight loss?

No. The metformin label carries one indication: improving glycemic control in type 2 diabetes. It appears in this category because it is often discussed alongside newer medications, not because of its approved use.

Why is there a generic metformin but no generic Ozempic?

Metformin has been approved long enough for generic applications to be filed and approved; the FDA label database lists dozens of them. The semaglutide products hold newer approvals, and no generic application for them appears in the database.

Weight lossTwo labels compared

Metformin vs Ozempic

Metformin and Ozempic are both approved to improve glycemic control in type 2 diabetes, and there the similarity ends. One is a generic tablet of a molecule in use for decades, the other a once-weekly injection of a GLP-1 receptor agonist. Even their boxed warnings are about entirely different risks. This page compares the two documents.

Metformin hydrochloride

Ingredient: Metformin hydrochloride
Approved for: Type 2 diabetesnot weight loss
Supply: Prescription
Boxed warning: WARNING: LACTIC ACIDOSIS
Pharmacy cost: $0.025 per tablet, capsule or pen, genericwhat pharmacies pay to buy it, not the price at the counter

REMEDYREPACK INC.. Label version 14, effective 19 May 2026.

Ozempic injection

Ingredient: Semaglutide
Approved for: Type 2 diabetes, with cardiovascular and kidney indicationsnot weight loss
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $331.98 per milliliter, brandwhat pharmacies pay to buy it, not the price at the counter

A-S Medication Solutions. Label version 1, effective 30 July 2026.

01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Label section	Metformin hydrochlorideMetformin hydrochloride	Ozempic injectionSemaglutide
Active ingredient	Metformin hydrochlorideMetformin hydrochlorideBiguanide	Ozempic injectionSemaglutideGLP-1 receptor agonist
Approved for	Metformin hydrochlorideType 2 diabetes	Ozempic injectionType 2 diabetes, with cardiovascular and kidney indications
Supplysame in both	Metformin hydrochloridePrescription	Ozempic injectionPrescription
What pharmacies payAcquisition cost, not retail	Metformin hydrochloride$0.025 per tablet, capsule or pen, generic	Ozempic injection$331.98 per milliliter, brand
Boxed warning	Metformin hydrochlorideWARNING: LACTIC ACIDOSIS	Ozempic injectionWARNING: RISK OF THYROID C-CELL TUMORS
What the FDA approved it for	Metformin hydrochloride Metformin hydrochloride tablets is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.	Ozempic injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Forms and strengths	Metformin hydrochloride Metformin Hydrochloride Tablets USP, 500 mg: White, biconvex, circular shaped film coated tablets with 'A' debossed on one side and '12' debossed on the other side Metformin hydrochloride tablets: 500 mg	Ozempic injection Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens Injection: 0.25 mg, 0.5 mg or 1 mg per 0.5 mL in a single-dose prefilled syringe
How the label says it is taken	Metformin hydrochloride Adult Dosage for Metformin Hydrochloride Tablets: Starting dose: 500 mg orally twice a day or 850 mg once a day, with meals Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks, up to a maximum dose of 2550 mg per day, given in divided doses Doses above 2000 mg may be better tolerated given 3 times a day with meals Increase dosage in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses twice daily Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) Do not use in patients with eGFR below 30 mL/minute/1.73 m 2	Ozempic injection Administer once weekly at any time of day, with or without meals. Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage. If a dose is missed, administer within 5 days of missed dose. Inject subcutaneously in the abdomen, thigh, or upper arm. Important Administration Instructions
Most common adverse reactions	Metformin hydrochloride most common adverse reactions (>5.0%) are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache.	Ozempic injection most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation.
Warnings and precautions	Metformin hydrochloride Lactic Acidosis: See boxed warning. Vitamin B 12 Deficiency: Metformin may lower vitamin B 12 levels. Measure hematological parameters annually and vitamin B 12 at 2 to 3 year intervals and manage any abnormalities. Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required	Ozempic injection Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC. Discontinue if pancreatitis is suspected. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. Never share an OZEMPIC pen between patients, even if the needle is changed. Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. OZEMPIC is not recommended in patients with severe gastroparesis. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue OZEMPIC if suspected and promptly seek medical advice. Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated.
Contraindications	Metformin hydrochloride Metformin hydrochloride tablets are contraindicated in patients with: Severe renal impairment (eGFR below 30 mL/min/1.73 m 2). Hypersensitivity to metformin. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Severe renal impairment (eGFR below 30 mL/min/1.73 m 2)	Ozempic injection Personal or family history of MTC or in patients with MEN 2. Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC.
Drug interactions	Metformin hydrochloride Table 3 presents clinically significant drug interactions with metformin hydrochloride. Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use Alcohol can potentiate the effect of metformin on lactate metabolism.	Ozempic injection Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.
Label version	Metformin hydrochloride19 May 2026	Ozempic injection30 July 2026

02Written by us

One disease, two very different documents

The metformin label describes a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes.

The Ozempic label covers glycemic control in adults, and two further indications metformin's label does not have: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and reducing the risk of kidney function decline, end-stage kidney disease and cardiovascular death in adults with chronic kidney disease.

The metformin label reaches younger patients; the Ozempic label reaches further into the complications of the disease.

03Written by us

The boxed warnings do not even overlap

Metformin's boxed warning is about lactic acidosis, a rare metabolic complication whose risk factors the label lists at length. Ozempic's boxed warning is about thyroid C-cell tumors observed in rodents, the warning shared by the GLP-1 receptor agonist class.

This is unusual for two products treating one disease, and it is a reminder that the risks named by the regulator follow the molecule, not the diagnosis.

04Written by us

A tablet regimen against a weekly injection

Metformin is taken orally with meals, starting at 500 mg twice a day or 850 mg once a day, increased gradually to a maximum of 2550 mg per day in divided doses. Ozempic is injected subcutaneously once weekly, starting at 0.25 mg with stepwise escalation.

The price gap between a generic tablet and a brand-name injectable is visible in the acquisition costs in the table above, drawn from CMS pricing data.

05Written by us

What this page does not tell you

It does not say which product a person should take, whether one should replace the other, or whether they should be combined. Those are treatment decisions that depend on a person's history and belong to a prescriber. The labels themselves do not compare the two molecules, and neither does this page beyond setting the documents side by side.

06Written by us

Common questions

Are metformin and Ozempic in the same drug class?: No. The metformin label describes it as a biguanide. The Ozempic label describes semaglutide as a GLP-1 receptor agonist. They are different classes with different mechanisms and different boxed warnings.
Is metformin approved for weight loss?: No. The metformin label carries one indication: improving glycemic control in type 2 diabetes. It appears in this category because it is often discussed alongside newer medications, not because of its approved use.
Why is there a generic metformin but no generic Ozempic?: Metformin has been approved long enough for generic applications to be filed and approved; the FDA label database lists dozens of them. The semaglutide products hold newer approvals, and no generic application for them appears in the database.

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

FDA prescribing information for Metformin hydrochloride
REMEDYREPACK INC.. Label version 14, effective 19 May 2026.
Full label on DailyMed Approval record ANDA077095
FDA prescribing information for Ozempic injection
A-S Medication Solutions. Label version 1, effective 30 July 2026.
Full label on DailyMed Approval record NDA209637

Each stripe is one section of the label, each division in a stripe one entry in that section. The red bar marks a boxed warning.

Other comparisons in this category

Page last updated 23 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.